How to Buy Bridgebio Pharma Stock
Bridgebio Pharma Inc
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions.
Bridgebio Pharma stock last closed at $66.96, up 1.24% from the previous day, and has increased 22.61% in one year. It has overperformed other stocks in the Biotechnology industry by 1.02 percentage points. Bridgebio Pharma stock is currently +26.94% from its 52-week low of $52.75, and -28.32% from its 52-week high of $93.42.
There are currently 195.49M shares of BBIO outstanding. The market value of BBIO is $13.09B. In the last 24 hours, 3.71M BBIO shares were traded.
How to Buy Bridgebio Pharma Stock
Wondering how to invest in Bridgebio Pharma stock? Here's how.
- Decide where to buy Bridgebio Pharma stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Bridgebio Pharma stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your details.
- Analyze Bridgebio Pharma stock: The Bridgebio Pharma ticker symbol is BBIO. Is Bridgebio Pharma stock a good investment? Should you buy shares of BBIO? How do BBIO's underlying business fundamentals look? Do top analysts think Bridgebio Pharma is a good buy? Why has BBIO's stock price moved recently? (Hint: Our stock market research website can help you figure out if BBIO is a good stock to buy).
- Place your BBIO purchase: Decide if you will purchase BBIO shares at the current market price or use a limit order to buy BBIO shares at a specific price.
- Track your BBIO investment: Create a watchlist to the latest updates on your investment in Bridgebio Pharma stock.
Step 1: Decide where to buy Bridgebio Pharma stock
You need a brokerage account to access the NASDAQ market and buy BBIO stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal info so you can invest in BBIO today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create a new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've opened your account on apps for stock market, you need to deposit funds:
Check out the tutorial below if you need help depositing funds into your brokerage account.
Step 4: Analyze Bridgebio Pharma stock
Once you have identified the best place to buy Bridgebio Pharma stock, it's absolutely critical to research their stock prior to investing, so you can wrap your head around the risk and opportunity.
Bridgebio Pharma quick stats
BBIO Overview
WallStreetZen was designed to help average investors do more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on BBIO's stock page.
How is BBIO stock valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge BBIO's true value.
You can do additional valuation research on BBIO's stock here.
BBIO Financials at a glance
Positive Financial Indicators:
- BBIO has $720.16M in cash and short term investments. This is enough to cover its annual cash burn of $435.39M.
- BBIO has cash burn of 435389000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the BBIO balance sheet.
Negative Financial Indicators:
- There are more long-term liabilities than short-term assets on the BBIO balance sheet.
- BBIO debt to equity ratio of -1.48 is negative.
- BBIO profit margin has gone up by 2.32 percentage points in the past year, but the company is still unprofitable.
- Total BBIO debt is still negative.
Is it a good time to buy BBIO stock, according to Wall Street analysts?
Out of 14 Equities analysts who monitor BBIO, the consensus analyst rating on BBIO is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest BBIO Analyst Upgrades/Downgrades
Geoff Meacham, a top 7% analyst from Bank of America maintains BBIO with a strong buy rating and raises their BBIO price target from $101.00 to $104.00, on Aug 11, 2026.
Tyler Van Buren, a bottom 50% analyst from TD Cowen maintains BBIO with a strong buy rating and raises their BBIO price target from $95.00 to $110.00, on Aug 11, 2026.
Sean Laaman, a top 27% analyst from Morgan Stanley maintains BBIO with a strong buy rating and lowers their BBIO price target from $98.00 to $97.00, on Aug 11, 2026.
Biren Amin, a bottom 4% analyst from Piper Sandler maintains BBIO with a strong buy rating and raises their BBIO price target from $111.00 to $115.00, on Aug 11, 2026.
Derek Archila, a top 3% analyst from Wells Fargo maintains BBIO with a strong buy rating and raises their BBIO price target from $98.00 to $102.00, on Aug 11, 2026.
Wells Fargo's Derek Archila raised their price target on Bridgebio Pharma (NASDAQ: BBIO) by 4.1% from $98 to $102 on 2026/08/11. The analyst maintained their Strong Buy rating on the stock.
BridgeBio Pharma reported its Q2 2026 earnings.
Factors Archila cited for their positive stance on the stock's setup included:
- Possible tailwinds for Attruby at ESC, which should further solidify stabilizers as first-line in TTR-CM.
- Three impending launches that should propel revenue growth momentum through 2027.
Earnings Report
For Q2 2026, Bridgebio Pharma reported:
- Loss per share of $0.78, which missed the Zacks Consensus Estimate of $(0.64) but beat Q2 2025’s $(0.95).
- Revenue of $243.68M, which beat the Zacks Consensus Estimate by 9.46% and, by 120.4%, Q2 2025’s $110.57M.
Management did not provide EPS and revenue guidance in its press release.
Co-Founder & CEO commented: “I'm excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-naïve, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we've established.
“Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for 2026/11/27, which is a level of strategic execution and discipline I'm proud of.
“Finally, with the $1B preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them.”
You can dig deeper into what analysts are forecasting on the Bridgebio Pharma stock forecast page.
BBIO Trading Indicators
BBIO Growth Numbers
Last year, BBIO revenue was $713.07M. Over the last five year, BBIO's revenue has grown by 62.6% per year. This was faster than the Biotechnology industry average of 32.53%.
Dive into BBIO's earnings and revenue performance here.
Latest Insiders Trades at BBIO
Over the past 12 months, insiders at BBIO have sold more shares than they have bought.
Neil Kumar, CEO of BBIO, was the latest BBIO insider to sell. They sold $601,871.09 worth of BBIO stock on Sep 17, 2026.
Dig into more about who owns BBIO shares here.
Can I get consistent income from BBIO stock?
No, Bridgebio Pharma doesn't provide an income stream by paying out dividends.
What others are saying about BBIO
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your BBIO purchase
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more info about buying stocks on eToro, watch the helpful video below:
Step 6: Track your BBIO investment
Now that you own some shares in BBIO, you'll want to keep up with your shares.
Make a watchlist to get notified of important updates regarding your BBIO stock.
BBIO Feed
How to Buy Stock in Bridgebio Pharma
To summarize, here are the 6 steps to buy Bridgebio Pharma stock:
- Decide where to buy Bridgebio Pharma stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Analyze Bridgebio Pharma stock
- Place your BBIO purchase
- Track your BBIO investment
If you need a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep track of your investment in Bridgebio Pharma, hit the button below to create your watchlist.
Other Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.